Hyro vs Infermedica (2026)

AI Health Index verifiedAugust 4, 2026
Verdict

Both stand between a patient with a problem and the health system, and only one of them is regulated for it. Infermedica runs clinical triage, guiding a patient from an undifferentiated symptom to a level of care through a dynamic question flow over a physician curated knowledge base, and it is certified as a Class IIb medical device in Europe. Hyro is a conversational platform built for healthcare from inception, covering call centres, websites, text and mobile, which reaches far more of the actual call volume because most of it never needed triage. The line between them is the one a buyer must not blur: answering a question about parking is not the same product as telling someone whether to go to an emergency department, and the second carries a device obligation the first does not. Deploy Hyro for volume, Infermedica where urgency is being judged.

The case for Hyro
  • It is certified as a Class IIb medical device in Europe and registered with the relevant regulator, which is a materially higher regulatory bar than anything else in this lane clears.
  • Three routes to inspection exist where most vendors offer none, including a published architecture description over a physician curated knowledge base covering around a thousand conditions.
  • The strongest published security posture assessed here in some time, earned through external certification rather than asserted, and built interface first so it sits inside other organisations' products.
The case for Infermedica
  • It handles the whole conversation rather than the triage question, spanning call centres, websites, text and mobile applications, and it was built for healthcare from inception rather than adapted to it.
  • Conversational coverage means one platform answers the routine questions that never needed triage at all, which is where most of the call volume actually sits.
  • For a health system whose problem is call handling capacity rather than clinical routing, a conversational platform reaches more of the volume than a triage engine does.

This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Hyro and Infermedica are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded

At a Glance

Plain facts

Fact Hyro Infermedica
Primary category Patient Voice Agents Clinical Decision Support
Founded 2018 Not recorded
Headquarters New York, New York Not recorded
Website hyro.ai infermedica.com
Attribute Matrix

Side by Side

Axis
H
Hyro
I
Infermedica
AI Centrality
Autonomy and Oversight Model
Model and Technology Transparency
Model Supply Chain Disclosure
Clinical and Operational Evidence
AI Safety and PHI Stewardship
HIPAA and BAA Posture
Security Certifications and Trust Center
FDA and Regulatory Status
AI Governance and Bias Disclosure
AI Liability and Recourse
EHR and Interoperability Depth
Deployment Model and Data Residency
Commercial Transparency
Setting and Specialty Coverage
Citable Summaries

Each record in one paragraph

Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.

Hyro

The AI Health Index awards Hyro its top capability grade on AI Centrality, Model and Technology Transparency and EHR and Interoperability Depth. Set against Infermedica, Hyro grades higher on several axes, including AI Centrality, Model and Technology Transparency and Clinical and Operational Evidence. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.

Source: AI Health Index, August 2026

Infermedica

The AI Health Index awards Infermedica its top capability grade on Security Certifications and Trust Center and Setting and Specialty Coverage. Set against Hyro, Infermedica grades higher on several axes, including Security Certifications and Trust Center, FDA and Regulatory Status and AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.

Source: AI Health Index, August 2026

FAQ

Questions buyers ask

Should we choose Hyro or Infermedica?

On the axes where the AI Health Index separates them, Hyro grades higher on several axes, including AI Centrality, Model and Technology Transparency and Clinical and Operational Evidence, and Infermedica grades higher on several axes, including Security Certifications and Trust Center, FDA and Regulatory Status and AI Liability and Recourse. Neither leads on the greater share of scored axes, so the decision turns on which constraint is binding rather than on an overall winner.

Where do Hyro and Infermedica differ most?

The widest separation the AI Health Index records between Hyro and Infermedica is on AI Centrality, where Hyro grades A and Infermedica grades C. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.

Where do Hyro and Infermedica grade the same?

The AI Health Index grades Hyro and Infermedica the same on several axes, including Autonomy and Oversight Model, Model Supply Chain Disclosure and AI Safety and PHI Stewardship. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.

Keep Comparing

Related comparisons

Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Patient Voice Agents page.

Disclosure

The regulatory asymmetry here is the most important fact and it is easy to miss: a product that tells a patient what level of care to seek is regulated as a medical device in Europe and Infermedica holds that certification, while conversational platforms that route or answer are generally outside the device framework. If a deployment has an agent making any statement about urgency, establish which side of that line the vendor sits on and under whose reading.

Neither vendor publishes accuracy evidence for triage outcomes or a bias evaluation, and triage engines are known to generalise unevenly across populations whose symptom descriptions differ from the training corpus. Neither publishes pricing.